M55 Stock Chart & Stats
€3.62
-€0.16(-4.79%)
At close: 4:00 PM EDT
€3.62
-€0.16(-4.79%)
Day’s Range― - ―
52-Week Range€1.14 - €4.22
Previous CloseN/A
Volume0.00
Average Volume (3M)357.00
Market Cap
€127.72M
Enterprise Value€318.75M
Total Cash (Recent Filing)€173.31M
Total Debt (Recent Filing)€35.09M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Nov 04, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding63,700,188
10 Day Avg. Volume50
30 Day Avg. Volume357
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)1.83
Price to Sales (P/S)0.68
P/FCF Ratio-1.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.24Price Target Upside72.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.56
Revenue Forecast (FY)€104.61M
Bulls Say, Bears Say
Bulls Say
MGC026 Clinical PotentialMGC026 has produced durable antitumor activity across multiple solid tumors, including heavily pretreated SCCHN patients. The results support continued expansion and potential movement into earlier-line combination treatment, creating a meaningful clinical opportunity for MacroGenics’ pipeline.
Improving Revenue And LossesRevenue growth and a substantial reduction in losses indicate improving operating performance and possible cost or revenue-mix benefits. Although MacroGenics is not yet profitable, this direction could strengthen its ability to fund development and improve earnings quality over the next several quarters.
Reduced LeverageLower debt-to-equity provides MacroGenics with a more manageable capital structure than in the prior year. Reduced leverage can limit balance-sheet pressure and preserve greater financial flexibility while the company advances clinical programs and works toward sustainable operating profitability.
Bears Say
Persistent Cash BurnContinued negative operating and free cash flow shows that MacroGenics is not yet funding its activities from operations. Ongoing cash consumption increases dependence on collaboration proceeds or external financing and may constrain the pace and breadth of future clinical development.
Unprofitable OperationsMacroGenics remains exposed to recurring losses despite meaningful year-over-year improvement in net margin. Negative operating profitability and declining equity indicate that clinical progress has not yet translated into a durable earnings base, leaving shareholder value sensitive to execution and funding needs.
Early-stage Clinical And Safety RiskThe encouraging MGC026 data are still generated in an early-stage study and require further validation in expansion cohorts and combination treatment. The high incidence of severe treatment-related adverse events also creates ongoing development and tolerability risk before broader advancement.
MacroGenics News
M55 FAQ
What was MacroGenics’s price range in the past 12 months?
MacroGenics lowest stock price was €1.14 and its highest was €4.22 in the past 12 months.
What is MacroGenics’s market cap?
MacroGenics’s market cap is €127.72M.
When is MacroGenics’s upcoming earnings report date?
MacroGenics’s upcoming earnings report date is Nov 04, 2026 which is in 8 days.
How were MacroGenics’s earnings last quarter?
MacroGenics released its earnings results on Aug 13, 2026. The company reported €0.277 earnings per share for the quarter, beating the consensus estimate of -€0.07 by €0.347.
Is MacroGenics overvalued?
According to Wall Street analysts MacroGenics’s price is currently Undervalued.
Does MacroGenics pay dividends?
MacroGenics does not currently pay dividends.
What is MacroGenics’s EPS estimate?
MacroGenics’s EPS estimate is -0.28.
How many shares outstanding does MacroGenics have?
MacroGenics has 63,700,188 shares outstanding.
What happened to MacroGenics’s price movement after its last earnings report?
MacroGenics reported an EPS of €0.277 in its last earnings report, beating expectations of -€0.07. Following the earnings report the stock price went down -0.578%.
Which hedge fund is a major shareholder of MacroGenics?
Currently, no hedge funds are holding shares in DE:M55
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MacroGenics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€6.24 (72.31% Upside)
€6.24 (72.31% Upside)
Blogger Sentiment
Neutral
DE:M55 Sentiment 75%
Sector Average 67%
Sector Average 67%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.95%
12-Months-Change
Fundamentals
Return on Equity
-31.27%
Trailing 12-Months
Asset Growth
40.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
MacroGenics
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
M55 Stock 12 Month Forecast
Average Price Target
€6.24
▲(72.31% Upside)